| Original language | English |
|---|---|
| Journal | British Journal of Dermatology |
| Volume | 186 |
| Issue number | 4 |
| Pages (from-to) | 746-748 |
| Number of pages | 3 |
| ISSN | 0007-0963 |
| DOIs | |
| Publication status | Published - 2022 |
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
No association between omalizumab use and risk of cancer : a nationwide registry-based cohort study. / Ali, Zarqa; Egeberg, Alexander; Thyssen, Jacob P. et al.
In: British Journal of Dermatology, Vol. 186, No. 4, 2022, p. 746-748.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - No association between omalizumab use and risk of cancer
T2 - a nationwide registry-based cohort study
AU - Ali, Zarqa
AU - Egeberg, Alexander
AU - Thyssen, Jacob P.
AU - Sørensen, Jennifer Astrup
AU - Vestergaard, Christian
AU - Thomsen, Simon Francis
N1 - Funding Information: Conflicts of interest: with no relation to the current work, A.E. has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galápagos NV, Sun Pharmaceutical Industries Limited, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, Dermavant Sciences, Inc., UCB, Mylan, Bristol Myers Squibb and Janssen. J.P.T. has attended advisory boards for Eli Lilly, Almirall, Arena Pharmaceuticals, Inc., Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi Genzyme, been an investigator for LEO Pharma, Sanofi Genzyme, Eli Lilly, AbbVie and Pfizer, and received speaker honoraria from LEO Pharma, Pfizer, Almirall, AbbVie, Eli Lilly, Regeneron and Sanofi‐Genzyme. C.V. has been a speaker, investigator and served at advisory boards for and received research grants from Novartis. S.F.T. has been a speaker, investigator, served on advisory boards and received research support from Novartis. Z.A. and J.A.S. declare they have no conflicts of interest.
PY - 2022
Y1 - 2022
UR - http://www.scopus.com/inward/record.url?scp=85123482479&partnerID=8YFLogxK
U2 - 10.1111/bjd.20941
DO - 10.1111/bjd.20941
M3 - Letter
C2 - 34878656
AN - SCOPUS:85123482479
VL - 186
SP - 746
EP - 748
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 4
ER -